TRUGLIF 25 MG TABLET

TRUGLIF 25 MG TABLET contains Empagliflozin as its active ingredient. Empagliflozin belongs to a class of medications known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. It works by inhibiting the reabsorption of glucose in the kidneys, leading to increased urinary glucose excretion and lower blood sugar levels. TRUGLIF 25 MG TABLET is prescribed for the management of type 2 diabetes mellitus.

Uses:

TRUGLIF 25 MG TABLET is indicated for the treatment of type 2 diabetes mellitus in adults. It helps lower blood sugar levels by promoting the excretion of glucose in the urine. This medication is typically prescribed as an adjunct to diet and exercise to improve glycemic control in individuals with diabetes.

Administration:

TRUGLIF 25 MG TABLET is usually taken orally with water, as directed by a healthcare professional. The recommended dosage is typically once daily, preferably in the morning, with or without food. It is important to follow the prescribed dosage instructions provided by the healthcare provider to achieve optimal glycemic control.

Side Effects:

Common side effects of TRUGLIF 25 MG TABLET may include urinary tract infections, genital yeast infections, increased urination, thirst, nausea, vomiting, diarrhea, dizziness, and fatigue. These side effects are usually mild and temporary, but if they persist or worsen, individuals should consult their healthcare provider. Rare but serious side effects may include ketoacidosis, kidney problems, and hypoglycemia. It is important to seek medical attention if any severe side effects occur.

Precautions:

Before using TRUGLIF 25 MG TABLET, individuals should inform their healthcare provider about any pre-existing medical conditions, allergies, or medications they are currently taking. This medication should be used with caution in individuals with kidney impairment, liver disease, heart failure, or a history of ketoacidosis. Regular monitoring of kidney function and blood sugar levels is recommended during treatment with TRUGLIF.

Contraindications:

TRUGLIF 25 MG TABLET is contraindicated in individuals with a known hypersensitivity or allergy to Empagliflozin or any of the components of the tablet. It should also be avoided in patients with severe kidney impairment or end-stage renal disease. This medication is not recommended for use in individuals with type 1 diabetes mellitus or diabetic ketoacidosis.

Conclusion:

TRUGLIF 25 MG TABLET, containing Empagliflozin, is a medication used for the management of type 2 diabetes mellitus in adults. It helps lower blood sugar levels by promoting urinary glucose excretion. Individuals with type 2 diabetes should consult their healthcare provider to determine if TRUGLIF is an appropriate treatment option for them.